5A Comillet, C Camus, S Nimubona, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis, September 1,2006,43 (5) :577 -584.
7Gonzalez-Pedraza Aviles A, Luis Hernandez R, Luna Avila J , et al. Urinary tract infection by Candida species. Atencion Primaria, 2006,38 (3) :147 - 153.
8Weerasuriya N, Snape J. A study of candida esophagitis in elderly patients attending a district general hospital in the UK. Diseases of the Esophagus, 2006,19 : 189 - 192.
9Paulo De , Oliveira JE, Milech A, et al. A fatal case of gastric mucormycosis and diabetic ketoacidosis. Endocrine Practice, 2002,8 (1):44-46.
10Khor BS, Lee MH, Leu HS, et al. Rhinocerebral mucormycosis in Taiwan. Journal of Microbiology, Immunology & Infection, 2003,36 (4) :266 - 269.
5Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis,2005,41:1455-1460.
6Rex JH,Pappas PG,Karchmer AW,et al. A randomized and blinded multicenter trial of high-dose fluconasole plus placebo versus fluconasole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis,2003,36:1221-1228.
7Steinbach WJ. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curt Drug Targets Infect Disord,2005 ,5 :203-210.
8Rees JR,Pinner RW,Hajjeh RA,et al. The epidemiologlcal features of invasive mycotic infections in the San Francisco Bay area, 1992-1993 :results of population-based laboratory active surveillance. Clin Infect Dis, 1998,27: 1138-1147.
9Nucci M,Marr KA. Emerging fungal diseases. Clin Infect Dis,2005,41:521-526.
